VJHemOnc Podcast Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms
Mar 31, 2025
Discover groundbreaking advancements in CAR T-cell therapy for lymphoma. Hear about CTX112, a next-gen allogeneic product showcasing impressive response rates and safety. Dive into the trials of trispecific CAR T-cells targeting multiple malignancies, highlighting a promising 70% overall response. Also discussed are innovative strategies like bisestronic therapies and a dose-dense approach that enhances treatment efficacy with minimal side effects. These insights from leading experts underscore the exciting future of lymphoma treatment.
AI Snips
Chapters
Transcript
Episode notes
CTX112 Enhances Allo-CAR Persistence
- CTX112 uses CRISPR-Cas9 to edit TCR and Regnase genes, enhancing allo-CAR T-cell persistence and proliferation.
- This allows effective activity with standard lymphodepleting chemo and less toxicity.
CTX112 Offers Strong Safety, Efficacy
- CTX112 has five gene edits to prevent GvHD, allo-rejection, and boost CAR T-cell function, including Regnase1 and TGF-beta receptor 2 knockouts.
- Early data shows 70% efficacy with 50% complete response and manageable safety profile.
Point of Care Tri-Specific CAR Success
- Point of care manufacturing shortens CAR-T production to 7-9 days, improving patient infusion rates to 94%.
- Tri-specific CARs targeting CD19,20,22 showed 83% CR in B-cell nodal lymphoma with favorable safety.